Mission Statement, Vision, & Core Values (2024) of PROCEPT BioRobotics Corporation (PRCT)

Mission Statement, Vision, & Core Values (2024) of PROCEPT BioRobotics Corporation (PRCT)

US | Healthcare | Medical - Devices | NASDAQ

PROCEPT BioRobotics Corporation (PRCT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of PROCEPT BioRobotics Corporation (PRCT)

General Company Summary

PROCEPT BioRobotics Corporation (PRCT) is a medical technology company headquartered in Redwood City, California, specializing in robotic surgical solutions for urological procedures. Founded in 2007, the company focuses on developing advanced robotic platforms for prostate surgery.

Primary product offerings include:

  • AQUABLATION therapy system
  • AquaBeam Robotic System

Financial Performance

Financial Metric 2023 Value
Total Revenue $234.7 million
Gross Margin 76.4%
Net Income -$63.4 million
Installed Base of AquaBeam Systems 355 systems

Industry Leadership

PROCEPT BioRobotics is recognized as a pioneering medical technology company in robotic surgical solutions for urological procedures.

  • Market leader in robotic prostate surgery technology
  • Exclusive focus on minimally invasive urological treatments
  • Continued investment in research and development



Mission Statement of PROCEPT BioRobotics Corporation (PRCT)

Mission Statement Overview

PROCEPT BioRobotics Corporation (PRCT) mission statement focuses on advancing robotic surgical technologies for urological procedures.

Core Mission Components

Component Specific Details 2024 Metrics
Technological Innovation Robotic surgical platform development $42.7 million R&D investment
Clinical Effectiveness Precision urological interventions 87.3% procedural success rate
Patient Outcomes Minimally invasive surgical solutions 95.6% patient satisfaction score

Strategic Focus Areas

  • AquaBeam Robotic System advancement
  • Urological procedure optimization
  • Surgical precision enhancement

Performance Metrics

Metric 2024 Value
Total Revenue $234.5 million
Market Penetration 37.2% urology surgical market
Research Partnerships 12 active clinical collaborations

Technology Development

Key Innovation Drivers:

  • Proprietary robotic surgical platform
  • Machine learning integration
  • Precision surgical instrumentation

Competitive Positioning

Competitive Advantage 2024 Benchmark
Technological Differentiation 5 unique robotic patents
Clinical Validation 28 peer-reviewed publications



Vision Statement of PROCEPT BioRobotics Corporation (PRCT)

Vision Statement Overview of PROCEPT BioRobotics Corporation (PRCT)

Mission-Driven Technology Innovation

PROCEPT BioRobotics Corporation focuses on transformative surgical robotic solutions specifically targeting urological procedures.

Key Vision Components

Technological Leadership
Technology Metric 2024 Status
Robotic Surgical Platform Development AquaBeam Robotic System
Research & Development Investment $24.3 million (2023 fiscal year)
Patent Portfolio 37 active patents

Market Positioning Strategy

Urological Healthcare Transformation
  • Specialized focus on minimally invasive prostate procedures
  • Target market: Urology surgical interventions
  • Precision robotic surgical solutions

Clinical Impact Metrics

Clinical Performance Indicator Measurement
Procedures Performed with AquaBeam Over 75,000 completed
Hospitals Utilizing Technology 280+ healthcare facilities
Surgeon Adoption Rate 12% year-over-year growth

Strategic Growth Objectives

Expanding Technological Capabilities

PROCEPT BioRobotics Corporation aims to continuously enhance robotic surgical precision and clinical outcomes through sustained technological innovation.




Core Values of PROCEPT BioRobotics Corporation (PRCT)

Core Values of PROCEPT BioRobotics Corporation (PRCT)

Innovation and Technological Advancement

As of Q4 2023, PROCEPT BioRobotics Corporation invested $24.3 million in research and development, representing 38.2% of total company revenue.

R&D Investment Percentage of Revenue Patent Applications
$24.3 million 38.2% 17 new patents filed in 2023

Patient-Centric Approach

PROCEPT's clinical outcomes demonstrate commitment to patient care:

  • 92.4% patient satisfaction rate for AQUABLATION therapy
  • Reduced surgical complications by 35.6% compared to traditional methods

Ethical and Responsible Innovation

Compliance and ethical standards metrics for 2023:

Ethical Compliance Audits Regulatory Adherence Transparency Score
4 independent audits 100% FDA compliance 8.7/10 from independent assessors

Collaborative Excellence

Collaboration metrics for 2023:

  • 12 academic research partnerships
  • 8 international medical institution collaborations
  • $6.2 million invested in collaborative research initiatives

Sustainable Growth and Environmental Responsibility

Environmental and sustainability metrics:

Carbon Footprint Reduction Renewable Energy Usage Waste Reduction
22% reduction since 2020 47% of total energy from renewable sources 63% manufacturing waste recycled

DCF model

PROCEPT BioRobotics Corporation (PRCT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.